ISRIB

ISRIB is a 2013 UCSF tool compound (Sidrauski / Walter lab) that allosterically activates eIF2B and reverses the chronic "translation shutdown" version of the integrated stress response. In mouse models it restores cognition lost to TBI weeks-to-months after injury, with effect persisting after dosing stops — the most mechanism-aligned compound known for Dylan's MMA subconcussive-impact thesis. But there are zero efficacy trials in humans, the only serious clinical program (Calico/AbbVie fosigotifator) failed Phase 2/3 ALS in January 2025 and the partnership ended November 2025, and a 2024 paper showed chronic ISRIB impairs the ubiquitin-proteasome system — a real safety flag for daily long-term use. Verdict: WATCH-LIST. Defensible 2-4 week research-chem trial if Dylan takes a real concussion; not yet a daily-driver brain-protection layer.

The integrated stress response (ISR), in plain English

Cells have a translation-shutdown switch — when they detect viral infection, misfolded proteins, oxidative damage, hypoxia, or amino-acid starvation, four sensor kinases (PERK, GCN2, PKR, HRI) phosphorylate the translation initiation factor eIF2α at serine 51. Phospho-eIF2α turns eIF2B from an enzyme into a brake — instead of recycling eIF2 between rounds of translation initiation, it sequesters eIF2 and global protein synthesis falls. Selectively, mRNAs with upstream open reading frames (uORFs) — including ATF4, CHOP, and stress-response transcription factors — are translated more. The cell stops making most proteins, makes a stress program instead.

This is protective when acute. In the chronic, low-grade form that follows TBI, aging, neurodegeneration, prion disease, Down syndrome, vanishing white-matter disease, and persistent UPR activation, ISR-mediated translation shutdown becomes maladaptive — synaptic plasticity proteins don't get made, hippocampal long-term potentiation (LTP) collapses, memory fails. The brain's "stress mode" gets stuck on.

What ISRIB does at the molecule

ISRIB is a small symmetric molecule (C₂₂H₂₄Cl₂N₂O₄, MW 451.34, CAS 1597403-47-8 for trans-isomer) that binds at the symmetric interface between two eIF2B(βγδε) tetramers. It "staples" them into a (βγδε)₂ octamer, which is competent to recruit eIF2Bα subunits and assemble into the active (αβγδε)₂ decamer. The decamer has restored guanine-nucleotide-exchange activity even in the presence of phospho-eIF2α — phospho-eIF2's inhibitory grip is allosterically overcome.

The clinically critical property: ISRIB only counteracts low-level ISR activation. At strong acute ISR signaling (high phospho-eIF2α stoichiometry), ISRIB is functionally inert — the cell's acute stress response remains intact. This is the "defined window of activation" (Rabouw et al., PNAS 2019). It explains why ISRIB does not produce the pancreatic toxicity seen with PERK inhibitors like GSK2606414 (Halliday et al., Cell Death & Disease 2015) — the secretory pancreas needs full UPR/ISR signaling, ISRIB doesn't shut it off, only the chronic low-grade brain ISR is suppressed.

Pharmacokinetics

• BBB penetration: excellent. Brain:plasma ratio approximately 1:1 in mouse; effectively not excluded.
• Half-life: ~8 hours in mouse; sufficient for once-daily dosing.
• IC₅₀: ~5 nM against ISR readouts.
• Solubility: poor in aqueous solution. White-to-off-white crystalline solid, soluble in DMSO and organic solvents. This is the main reason drug development failed — formulating a reproducible oral product with predictable PK is hard. Mouse studies use intraperitoneal injection in DMSO/PEG/saline vehicle; oral bioavailability of ISRIB itself is poor. Calico/AbbVie's fosigotifator (ABBV-CLS-7262) is a structurally distinct CNS-penetrant analog with improved drug-like properties, not ISRIB itself.
• Effective mouse dose: 0.25 mg/kg IP in the canonical Sidrauski / Chou / Krukowski experiments; some studies use up to 2.5 mg/kg/day. Higher doses (5 mg/kg) caused excess mortality in one Alzheimer's model (signal that the therapeutic window is real but bounded).

Plain-English summary

ISRIB tells brain cells: resume normal protein synthesis, even though the stress sensors are still on. It does not stop the upstream stress (no effect on phospho-eIF2α levels themselves), and it does not interfere with the acute stress response. It specifically reverses the chronic, smoldering translation block that follows brain injury and aging. For a brain whose synaptic plasticity is being held hostage by stuck-on ISR, ISRIB lets it make the proteins it needs to learn again.